Category Archives: Immunology

Trump says he may now be ‘immune’ to the coronavirus. Here’s what we know about COVID-19 and immunity. – Poynter

Since his return from Walter Reed National Military Medical Center, President Donald Trump has repeated that he may now be immune to the coronavirus.In a videoreleased shortly after he arrived back at the White House, he said, Now Im better, and maybe Im immune, I dont know.

In a55-minute interviewon Fox Business, he made several claims about his health and COVID-19 immunity, saying, When you catch it you get better, and then youre immune, and jokingly referred to himself as a perfect physical specimen.

But medical experts say there are still a lot of unknowns about COVID-19 immunity.

Do all recovered COVID-19 patients become immune, regardless of the severity? For how long? Will the virus behave like the flu, requiring a vaccine each year? How do we achieve herd immunity?

We spoke with immunology and infectious disease experts about what they have learned and still dont know about COVID-19 and immunity.

Heres what we found out.

A person achieves immunity to a disease when the bodys immune system has fought off the virus once and is now strengthened to resist further attack. The immune system has a kind of memory for previous pathogens, allowing the body to have a quicker, stronger response the next time it encounters a past invader.

This can happen naturally or via vaccine.

Medical experts say its hard to know for certain the strength and length of immunity for recovering COVID-19 patients, because its a new virus and not enough studies have been done. However, there are indicators that suggest there is some natural protection against the disease post-recovery.

The biggest clue is that recovered patients rarely get reinfected with COVID-19, experts said, especially when considering the huge number of people who have been infected with the virus around the world.

The very high-level picture is pretty stable, said Dr. Sarah Fortune, chair of the Immunology and Infectious Diseases department at Harvard T.H. Chan School of Public Health.

Both the clinical data and the animal studies suggest that there is meaningful protection against disease, Fortune said. Its not as if youre seeing rampant recurrent infections with recurrent severe symptoms. Its not as if there are no cases, but by and large youre seeing substantial protection against disease.

Experts also said previous studies that looked at common cold coronaviruses showed that people develop immunity for extended periods of time (at least a year), though it varied slightly from case to case.

There may be some differences in the level of immunity for those who had a serious infection, versus those who only experienced mild symptoms, researchers say. Generally, patients who dealt with a severe infection are likely going to have a higher antibody count.

But that doesnt mean that your mild infection isnt providing you enough immunity to protect you against the disease, Fortune said. Even if its lower, it appears to be completely proficient in protecting you against the disease. And, in most of the people who are infected, they develop a mild case and we arent seeing many reinfections.

Theres no standard time frame for immunity after someone recovers from COVID-19. Different public health groups have different estimates, with the most conservative being aboutfour months

Researchers say its likely that people are immune for longer, but note that with a rapidly spreading disease that has no cure, people should keep their guard up rather than return to life as normal and put themselves and others at risk.

One common misconception immunologists raised is the public perception of immunity in general, with many people thinking youre either immune or youre not. Thats not how it works.

Protection is not like a light switch, its like a dimmer switch, Fortune said. You will be more protected in the beginning, and over time that protection might wane, but its not going to just go away.

For example, as a persons immunity wanes, they may eventually get infected from the virus again, but not actually get sick. Or even further out, they may get infected and then have mild symptoms but nothing severe.

The takeaway: The loss of immunity is gradual, not drastic.

Registered Nurse Kath Olmstead gives volunteer trial participant Melissa Harting a blinded study experimental vaccine for COVID-19 developed by the National Institutes of Health and Moderna Inc. at the United Health Services facility, Monday, July 27, 2020. (AP Photo/Hans Pennink

The flu is a respiratory virus like the coronavirus, but its also quite different. The flu rapidly shifts and mutates, making it more resistant to long-term immunity. Thats why there is a new vaccine each year.

If the virus that causes COVID-19 continues to behave like other coronaviruses, people will likely have more stable immunity from a limited vaccination schedule.

Theres no evidence, so far, that people will need to be vaccinated each year because of the virus mutating, said Dr. Stanley Perlman, a professor of microbiology and immunology at the University of Iowa. That may be because of their immunity waning, but not because the virus is changing.

Fortune agreed. Theres no evidence that Sars-Cov-2 (the virus that causes COVID-19) is going to, or has undergone, a really dramatic re-shuffling that makes it escape either a natural immunity or even a vaccine-induced immunity, she said. Thats not to say that its not possible there wont be a new one in the future, but just that the virus doesnt share the same characteristics of the seasonal, whole-scale remaking of itself that the flu does.

Positive test results dont guarantee immunity. The presence of antibodies only means that the person has been exposed to the virus in the past.

How sensitive, or how good, the antibody test is, and the amount of antibodies a person has, weighs heavily on whether or not they would be considered immune from the virus.

The same thing is true with a PCR diagnostic COVID-19 test.

Some people have very positive PCR tests and thats more of a worry than someone with fluctuating PCR tests negative one day, positive the next because they have less of a viral load, Perlman said. Its the same thing with antibodies. You can test positive for antibodies but have so little that it doesnt really protect you, or you can have a high number of antibodies, which means youre better protected. The amount matters.

Herd immunity is the idea that when enough people in a population are immune, either by having the infection or receiving a vaccine, the virus will have trouble spreading. Thats because an infected person is less likely to encounter a non-immune person to pass it on to, making them a dead-end in the chain of transmission.

When that happens enough times on a large scale, it drives its rate down and eventually gets the disease under control, but it doesnt necessarily eradicate it.

The U.S. is still considered far from adequate COVID-19 herd immunity, and experts say there would have to be many more cases and deaths before we get there if a vaccine doesnt arrive first. Fewer than 1 in 10 Americans show signs of past infection as of late July, according to a Sept. 25studypublished in The Lancet journal.

So, experts agree that the ideal way to achieve herd immunity is with a vaccine. While some immunity within a population is better than none, with a virus that spreads through the air, the higher the number of people who are immune, the better.

Different numbers have been tossed around by scientists on just how much of the population needs to be immune in order for herd immunity to work well. The mathematical model for Sars-Cov-2 which is derived based on the virus transmission characteristics and on how the population behaves puts it around 60-70 people out of every 100.

For the most highly contagious diseases, like measles, scientists say about 94% of the population needs to be immunized to achieve that level of protection.

That doesnt mean that it goes away when we reach herd immunity, it just means that youre not propagating the epidemic, Fortune said. People should have that in mind with herd immunity, and with the future, its not like one day, we achieved herd immunity and its gone.

This article was originallypublished by PolitiFact, which is owned by the Poynter Institute, and is republished here with permission. See the sources for this articlehereand more of their fact-checkshere.

More here:
Trump says he may now be 'immune' to the coronavirus. Here's what we know about COVID-19 and immunity. - Poynter

Revealing Key Immunology Insights with Spatial Analysis – Technology Networks

The immune system is a complex, dynamic and heterogeneous entity, making it particularly challenging to explore. To gain a more comprehensive understanding of immunity, scientists must be able to characterize specialized cell types, the functional states of individual cells and information on spatiotemporal resolution within healthy and diseased tissues.Download this listicle to learn more about:

Continued here:
Revealing Key Immunology Insights with Spatial Analysis - Technology Networks

COVID-19 Preventative Measures Associated With Reduced Asthma Hospitalizations – PR Web

This would suggest that asthma control improved during the pandemic. It illustrates the importance of environmental factors when it comes to treating and managing patients with asthma. - Atsushi Miyawaki, MD, PhD

MILWAUKEE (PRWEB) October 13, 2020

According to new research published in The Journal of Allergy and Clinical Immunology: In Practice (JACI: In Practice), preventative measures used to slow the spread of COVID-19 in Japan have also lowered the rate of hospitalizations for asthma.

Researchers used the Diagnosis Procedure Combination inpatient database to conduct their research. The data on all hospitalizations per week across 272 hospitals nationwide from December 30, 2019, to May 31, 2020, was gathered and compared to the same periods in 2017, 2018, and 2019.

A total of 16,317 hospitalizations for asthma were observed in the study. Asthma hospitalizations in 2017-2019 and 2020 showed parallel trends until week eight. Researchers observed a decline in asthma hospitalizations from week nine onwards in 2020. Hospitalizations for COVID-19 were first observed during week seven of 2020. Further analysis found the average number of asthma hospitalizations significantly decreased during weeks nine to 22 in 2020 compared to 2017-2019 for both children and adults.

Asthma hospitalizations usually indicate that an individuals asthma is not currently under control, said Atsushi Miyawaki, MD, PhD, corresponding author for the study. This would suggest that asthma control improved during the pandemic. It illustrates the importance of environmental factors when it comes to treating and managing patients with asthma.

One possible explanation for the results is that increased hygiene by individuals to reduce their chances of contracting COVID-19 would also reduce their exposure to asthma triggers. Enhanced preventative measures by individuals concerned that COVID-19 may trigger asthma, such as frequent cleaning and reduced smoking, may also have helped to remove allergen triggers. Individuals may have also been more likely to use preventative asthma medications. Another explanation might be that community prevention measures may have helped suppress other respiratory infections, which can cause asthma exacerbations.

You can learn more about asthma and COVID-19 on the American Academy of Allergy, Asthma & Immunology website, aaaai.org.

The American Academy of Allergy, Asthma & Immunology (AAAAI) represents allergists, asthma specialists, clinical immunologists, allied health professionals and others with a special interest in the research and treatment of allergic and immunologic diseases. Established in 1943, the AAAAI has more than 7,100 members in the United States, Canada and 72 other countries. The AAAAIs Find an Allergist/Immunologist service is a trusted resource to help you find a specialist close to home.

Share article on social media or email:

See the original post:
COVID-19 Preventative Measures Associated With Reduced Asthma Hospitalizations - PR Web

UCB Snags Eli Lilly UK Research Site, Plans to Invest 1 Billion Over Five Years for R&D – BioSpace

UCB is investing more than 1 billion (roughly 1.29 billion USD) over five years to expand its research and development (R&D) capabilities in the U.K., which will include a transition to a newly acquired 47-acre R&D campus from Eli Lilly located in Windlesham, Surrey.

The global neurology- and immunology-focused biopharma announced Friday it has signed an agreement to acquire the new campus from Eli Lilly to support the companys cutting-edge research and development, early manufacturing and commercialization of medicines for patients with severe neurological and immunological diseases.

Formerly, the facility was Eli Lillys second-largest research site worldwide. Exactly one year ago, Eli Lilly announced it was closing the doors to its neuroscience-focused Erl Wood research center in Surry. The Indianapolis, IN.-based pharmaceutical company said it planned to do so by the end of 2020, effectively impacting 270 staff members and resulting in possibly 80 redundancies. Approximately a third of the non-laboratory workers at the Eli Lilly site was moved to another nearby location. This news followed some months after the company also announced it was cutting 250 jobs at its 1,400-employee factory in Eastern France for the purposes of modernization.

The new U.K. site will be home to one of the companys three global R&D hubs, in addition to those located in Belgium and the U.S. Following completion of the acquisition, which is expected for November 2020, UCB will perform a complete state-of-the-art refurbishment of the campus before staff at its current U.K. headquarters in Slough, Berkshire, move in.

While UCBs five-year plan to invest 1 billion in the U.K. effort will include the new facility, both UCB and Eli Lilly have yet to disclose the financial details on the acquisition. According to UCB, the five-year, 1 billion investment will also support the addition of 650 high-value jobs in scientific research, translational medicine, clinical development, early manufacturing and commercial roles in the region.

We have a strong track record of discovering medicines in the UK which go on to make a difference to the lives of patients worldwide, said UCB CEO, Jean-Christophe Tellier, in a statement. I am delighted to have signed an agreement to secure this new campus for our U.K. hub, from which our scientists will be able to continue to develop their extensive collaborations with some of the most innovative universities, bio-techs and medical research charities, bringing even greater benefit for patients.

Tellier added, This new UK site will not only support our ambitions for future drug discovery but will be well-placed to enable us to achieve our 2030 global sustainability goals and provides an environment which supports the physical and mental wellbeing of our people essential to helping us thrive.

This isnt the first acquisition under UCBs belt. Earlier this summer, UCB announced the news that it had acquired clinical-stage pharmaceutical company Engage Therapeutics for an upfront cash payment of $125 million. Additional potential milestone payments of up to $145 million were also part of the deal. Engage was in the process of developing alprazolam, a single-use therapeutic for the rapid treatment of active epileptic seizures. The acquisition gave UCB worldwide rights to the therapy, in addition to giving them the power to take over further clinical development, submission, launch and commercialization procedures.

Originally posted here:
UCB Snags Eli Lilly UK Research Site, Plans to Invest 1 Billion Over Five Years for R&D - BioSpace

Virtually Supported Home Peanut Introduction is Viable Option – MD Magazine

With the impact of the coronavirus disease 2019 (COVID-19) lockdown measures continuing to be felt across the US, access to healthcare resources for the management of allergic disease are still limited.And although in-person services may be offered by clinics, concern or fear over exposure to the virus can certainly hinder patient use of such services.

And yet, certain allergic conditions, such as peanut allergies in high-risk infants, require expedited assessments and active management.

A report written by Douglas Mack, MD, Assistant Clinical Professor, Pediatrics, McMaster University, and colleagues detailed the first known use of a virtually supported home peanut introduction in infant patients at risk of developing peanut allergy. The program was conducted earlier this year in April.

Prior to initiation of the virtual program, infants were screened for eligibility in a private-practice allergist setting using the telehealth platform Doxy.me.

Patients were eligible if they had physician-diagnosed severe eczema, physician diagnosed egg allergy, SPT3 mm or 0.35 kU/L without prior ingestion, perceived high-risk by caregiver, or had caregiver anxiety to introduce a particular food.

Excluded from the study were patients with a history of systemic IgE-mediated reaction to the food in questions; had certain underlying conditions, such as uncontrolled asthma, cardiac conditions, respiratory conditions; or used a beta-blocker.

During this first consultation, parents or guardians were informed about the risks and benefits of either prolonging peanut avoidance until the first in-person visit or participating in the virtually-support food introduction process.

If they chose to proceed with the program, then consent was obtained, and they were prescribed an epinephrine autoinjector and rupatadine.

In the next visit with the physicians, caregivers were then informed about the process, possible symptoms, and treatment.

Then they were instructed to prepare peanut putter by dissolving 2 teaspoons of it in 2-3 teaspoons of hot water, then letting it cool.

Caregivers then gradually introduced 2 g of peanut butter every 10-15 minutes over 45 minutes 1 hour.

If any symptoms occurred, the guardian used the telehealth program to contact the physicians for further assessment. If the physicians were unable to be reached, then caregivers were instructed to administer epinephrine and/or antihistamine or contact emergency medical services.

However, if no symptoms occurred, then the physicians would advise ingestion of the food of similar or increased amounts 2-3 per week.

Mack and colleagues referenced recent clinical guidelines that provide a framework for at-home management of anaphylaxis. They suggest that using these guidelines would be necessary in the event of such reactions during the virtually supported food introduction.

Nonetheless, they noted that no reactions were reported during the food introduction process, which they considered to be consistent with the current evidence that anaphylaxis is rare and non-threatening with first ingestion in infancy. Thus, they emphasized that mild reactions can generally be managed with antihistamine and/or observation.

Even before COVID-19, lack of allergist resources presented significant barriers to the introduction of peanut to at-risk patients where there was hesitance, they wrote.

During COVID-19, the need to provide alternative forms of care is heightened. Virtually supported introduction may represent a future option after COVID-19 to improve access for patients who live in remote areas, or otherwise have limited access to allergists, or for clinicians with overburdened clinics.

They acknowledged that the implementation of such a strategy requires formal evaluation of safety, cost-effectiveness, caregiver/physician acceptability, sustainability, and patient satisfaction.

The report, Virtually supported home peanut introduction during COVID-19 for at-risk infants, was published online in The Journal of Allergy and Clinical Immunology: In Practice.

View post:
Virtually Supported Home Peanut Introduction is Viable Option - MD Magazine

argenx to Report Third Quarter 2020 Financial Results and Business Update on October 22, 2020 – Stockhouse

October 15, 2020 Breda, the Netherlands / Ghent, Belgium argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that it will host a conference call and audio webcast on Thursday, October 22, 2020 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its third quarter 2020 financial results and provide a business update.

A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one year following the call.

Dial-in numbers: Please dial in 15 minutes prior to the live call.

Belgium 0800 389 13 France 0805 102 319 Netherlands 0800 949 4506 United Kingdom 0800 279 9489 United States 1 866 270 1533 International 1 412 317 0797

About argenx argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx is evaluating efgartigimod in multiple serious autoimmune diseases, and cusatuzumab in hematological cancers in collaboration with Janssen. argenx is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx has offices in Belgium, the United States, and Japan. For more information, visit http://www.argenx.com and follow us on LinkedIn at https://www.linkedin.com/company/argenx/ .

For further information, please contact:

Beth DelGiacco, Vice President, Investor Relations (US) +1 518 424 4980 bdelgiacco@argenx.com

Joke Comijn, Director Corporate Communications & Investor Relations (EU) +32 (0)477 77 29 44 +32 (0)9 310 34 19 jcomijn@argenx.com

Read more from the original source:
argenx to Report Third Quarter 2020 Financial Results and Business Update on October 22, 2020 - Stockhouse

Allergy Partners Discusses Ways to Differentiate Between Cold, the Flu, or COVID-19 – Benzinga

ASHEVILLE, N.C., Oct. 16, 2020 /PRNewswire-PRWeb/ -- Here is how you can tell the difference In the best of times, it can be hard to tell the difference between symptoms of a cold and the flu. With the COVID-19 pandemic, understanding what these symptoms are versus those of COVID-19 is even more important than ever.

Facts The virus causing COVID-19, called SARS-CoV-2, is part of a family of viruses called Coronaviruses. This is a large family of viruses that cause illnesses ranging from the common cold to more severe respiratory illnesses. Coronaviruses can develop in animals and, through mutation, come to infect humans. SARS-CoV-19 is a mutated coronavirus that emerged in China in late 2019. It can cause severe respiratory illnesses such as pneumonia and can be fatal. Yet, in some people the symptoms can be mild. You should seek immediate medical care for any of the following:

Because cold and flu symptoms can appear like some of the symptoms of COVID-19, it is very important to monitor your symptoms closely. The Centers for Disease Control (CDC) has an interactive symptom tracker you can use to determine if you should seek care for possible COVID-19 infection at: https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.

Most importantly, keep in contact with your Allergy Partners physician. Our offices remain open and we are offering Telemedicine services to make sure you and your family remain well during this challenging time. Our experienced allergists are anxious to discuss any questions or concerns you may have about COVID-19 and how we can best manage your health together.

WILLIAM A. MCCANN, M.D. Born and raised outside of Baltimore, Dr. McCann has called North Carolina home since completing medical school. After his pediatrics training at Duke, he practiced general pediatrics for three years in Hendersonville. During this time, he realized that his passion lies in the treatment of allergies and asthma. After a brief sojourn in Augusta, Georgia for allergy and immunology training, he returned to Western North Carolina and joined Allergy Partners.

RICHARD L. WASSERMAN, M.D., PHD. Dr. Wasserman received his medical degree from the Mt. Sinai School of Medicine/University of Texas Southwestern Medical School and completed his Pediatrics Residency at Children's Hospital of Philadelphia. Dr. Wasserman completed fellowship training in Bone Marrow transplantation/Immunology at the Children's Hospital of Philadelphia, Postdoctoral Cancer/Immunology at the University of Texas Southwestern Medical School, and Immunology/Rheumatology at The Rockefeller University.

Allergy Partners, PLLC is the nation's largest single specialty practice with multiple locations across the United States. Our allergists provide evaluation and treatment of following conditions:

Allergic Rhinitis | Asthma | Food Allergies | Eczema Hives | Sinus Problems | Stinging Insect Allergies | Immune Deficiencies | Chronic Cough | Drug Allergies Recurrent Infections | Eosinophilic Esophagitis

SOURCE Allergy Partners

See the original post here:
Allergy Partners Discusses Ways to Differentiate Between Cold, the Flu, or COVID-19 - Benzinga

Research Associate job with UNITED ARAB EMIRATES UNIVERSITY | 229041 – Times Higher Education (THE)

Job Description

We offer a research associate/postdoc position in field of Immunology for highly motivated candidate at the department of Biology, College of science, UAE University. In this project, we would like to elucidate the role of the B cells in chronic allergic skin reactions. Characterization of different immune cells involved in allergic skin reactions will be delineated with particular focus on molecular mechanisms.

Minimum Qualification

A successful applicant should have master degree (PhD in case of postdoc) with strong background in Immunology (A must) along with working knowledge of basic techniques like FACS, cell culture, molecular biology and/or bioinformatics. Applicant should be willing to work with animal models. Excellent communication skills, fluency in English and the ability to work independently and together with a team are highly desired. Applicants with above expertise should ONLY apply. The candidates should send their electronic application as single PDF that should include a brief cover letter describing their research experiences related to above field with motivation, CV, and names of two potential referees

Preferred Qualification

M.Sc Life Sciences with major in Immunology

Expected Skills/Rank/Experience

Special Instructions to Applicant

Division College of Science - (COS)

Department Biology - (COS)

Job Close Date 31-01-2021

Job Category Academic - Research Assistant

Salary Salary is commensurate with experience

Excerpt from:
Research Associate job with UNITED ARAB EMIRATES UNIVERSITY | 229041 - Times Higher Education (THE)

Second informative webinar in series addresses COVID-19 vaccines, immunology – Observer Online

ThinkND and the Eck Institute for Global Helath presented their second webinar of the series Consider This! Simplifying the COVID-19 Conversation Monday. Thissession was titled Vaccines and the Immunology of COVID-19, and covered COVID-19 vaccines, the clinical trial process and immunity. The goal of the series is to fight against common misconceptions about COVID-19.

Mondays webinar hosted two speakers: Brian Baker, Rev. John A. Zahm professor and department chair of chemistry and biochemistry, and Jeffrey Schorey, George B. Craig Jr. professor in the department of biological sciences.

To begin, co-hosts Mary Ann McDowell, an associate professor of biological sciences and a member of the Eck Institute for Global Health, and Heidi Beidinger-Burnett, director of the Eck Institute for Global Health and president of the St. Joseph County Board of Health, answered a question emailed to them by a student in regards to last weeks session, and addressed local news concerning the pandemic.

Viewers were informed that COVID-19 cases are currently rising in St. Joseph County, and Indiana set a new state record of new COVID-19 cases in a day on Saturday, with 1,945 reported new cases.

Schorey and Baker then explained the national news surrounding President Donald Trumps claim that he will utilize emergency-use authorization (E.U.A.) to speed up the U.S.s COVID-19 response.

To describe the E.U.A., Schorey used the analogy of a fast pass at an amusement park. Usually, companies must wait in line to get their vaccines approved by the Food and Drug Administration (FDA), but the E.U.A. serves as a kind of fast pass.

Next, on the segment McDowell and Beidinger-Burnett call Rumor Has It, Schorey and Baker spoke to the claim that once an individual contracts COVID-19, they are immune for 90 days.

Schorey and Baker said it is too early to tell how long immunity will last, as well as to what extent it will protect recovered COVID-19 survivors.

With that being said, Baker believes there will be long-lasting immunity from COVID-19. Schorey said similarities between the current COVID-19 virus and the SARS-CoV-1 virus give us hope there will be fairly good immunity developed from COVID-19, just as there was from SARS-CoV-1.

In regards to immunity, Schorey and Baker emphasized there are differences in peoples immune responses. Schorey said he would expect a stronger immune response from people who naturally got COVID-19 and recovered, than from those who were vaccinated.

The phases of vaccine development were then discussed by the speakers. First, the preclinical phase is conducted, which consists of animal testing. Next are Phases I and II, which test the vaccine with humans with special attention given to safety. Then, in Phase III, the vaccine is given to a large number of people to test for efficacy. Lastly, Phase IV consists of the deliverance of the vaccine to the public.

It is important that a high volume of people receive the vaccine in Phase III to account for varying immune responses from different populations of people, the speakers said.

Throughout the session, the audience submitted questions, which Schorey and Baker answered. Additionally, all are welcome to email additional questions to [emailprotected].

Consider This! airs live every week on Monday evenings from 6 to 7 p.m. Each session addresses a new topic related to COVID-19. Next weeks session is titled Masks, Distancing and Public Health, and registration for the webinars can be found under the Eck Institute for Global Healths website.

Read the original here:
Second informative webinar in series addresses COVID-19 vaccines, immunology - Observer Online

Innovent Announces the Appointment of Dr. Yong Jun Liu as the President of the Group – BioSpace

SAN FRANCISCO and SUZHOU, China, Oct. 14, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, today announces the appointment of Dr. Yong Jun Liu, a renowned world class scientist and successful leader in biopharmaceutical industry, as the president of the group. Reporting to Dr. Michael Yu, founder, chairman and CEO of the group, Dr. Liu will be mainly responsible for group's global R&D, portfolio strategy, business development as well as international operation.

As a world renowned scientist in immunology, oncology and translational medicine, Dr. Liu has over 30 years' experiences in both academic institutions and top global pharmaceutical companies. Dr. Liu received his MD's degree in internal medicine from Bethune Medical University in 1984 and Ph.D. degree in Immunology from University of Birmingham, UK in 1989. After two years postgraduate training in the same laboratory at University of Birmingham, he joined multinational pharmaceutical company Schering-Plough in 1991 as a Senior Scientist at Schering-Plough Lyon France. In 1997, he moved to the DNAX Research Institute, a biotech company owned by Schering-Plough in Palo Alto, California, as a Principal Staff Member. In 2002, Dr. Liu was recruited by the University of Texas (UT), MD Anderson Cancer Center, as the Vivian Smith Distinguished Chair Professor, Chairman of the Department of Immunology and the founding Director of the Center for Cancer Immunology Research (CCIR). In 2011, Dr. Liu was recruited by the Baylor Research Institute as the Chief Scientific Officer and the Director of the Baylor Immunology Research Institute. After more than 10 years at the academia, Dr. Liu was recruited by Medimmune, a biopharmaceutical subsidiary of AstraZeneca, as Chief Scientific Officer and global Head of Research in 2014. Before joining Innovent, Dr Liu served as the global Head of Research at Sanofi from 2016 to 2020.

Dr. Liu has remarkable academic achievements and rich experience in research institutions. As one of the top cited scientists in Immunology with over 94,000 citations, Dr. Liu published over 260 scientific papers in Nature, Science and other top academic journals. These studies provide a number of key targets for drug development in the area of inflammation, autoimmune diseases, allergy and oncology, such as thymic stromal lymphopoietin (TSLP), OX40 (CD134), plasma cell like dendritic cells (pDCs).

As key executive R&D leader in multiple global pharmaceutical companies for nearly a decade, Dr. Liu has made remarkable achievements in strengthening drug research capability and enriching early stage innovative pipelines in major therapeutic areas, especially in the fields of immunology and oncology. His leadership skill and strategic thinking guided R&D functions to effectively develop first-in-class and best-in-class drugs during his tenure in various global pharmaceutical companies.

"Warmly welcome Dr. Liu and we are more than excited to have him join Innovent," said Dr. Michael Yu, founder, chairman and CEO of Innovent. "Dr. Liu is not only a renowned scientist with strong academic background but also a powerful manager with extraordinary leadership and rich experience in drug research and development. His successful experience in strengthening the drug research capability and enriching innovative pipeline is an ideal fit to Innovent's strategic goal of developing a first-in-class pipeline for the global market. We believe that Dr. Liu's leadership will bring added benefits to further strengthen our R&D capability and solidify our efforts in building a global R&D platform and developing a more innovative pipeline."

"Innovent is a rapid growing and innovative biopharmaceutical company," said Dr. Liu. "I'm very pleased to join such a company with strong emphases on science and innovation, high execution capability and so many talented and passionate people. I look forward to working with our global team to develop innovative life changing medicine that benefit patients of the world."

About Innovent

Inspired by the spirit of "Start with Integrity, Succeed through Action," Innovent's mission is to develop and commercialize high quality biopharmaceutical products that are affordable to ordinary people. Established in 2011, Innovent is committed to developing, manufacturing and commercializing high quality innovative medicines for the treatment of cancer, metabolic, autoimmune and other major diseases. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.

Since its inception, Innovent has developed a fully-integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities. Leveraging the platform, the company has built a robust pipeline of 23 valuable assets in the fields of cancer, metabolic, autoimmune diseases and other major therapeutic areas, with four products, TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection) officially approved for marketing in China, four assets in Phase III or pivotal clinical trials, and additional 15 molecules in clinical trials. TYVYT has been the only PD-1 inhibitor included in the NRDL since 2019.

Innovent has built an international team with expertise in cutting-edge biological drug development and commercialization. The company has also entered into strategic collaborations with Eli Lilly, Roche, Adimab, Incyte, MD Anderson Cancer Center, Hanmi and other international partners. For more information, please visit: http://www.innoventbio.com.

View original content:http://www.prnewswire.com/news-releases/innovent-announces-the-appointment-of-dr-yong-jun-liu-as-the-president-of-the-group-301152724.html

SOURCE Innovent Biologics, Inc.

Company Codes: HongKong:1801, OTC-PINK:IVBIY

More here:
Innovent Announces the Appointment of Dr. Yong Jun Liu as the President of the Group - BioSpace